10-K: Nkarta Shifts Focus to Autoimmune, Reports Reduced Losses

Nkarta, Inc. reports a strategic pivot to autoimmune disease therapies with its lead candidate NKX019, alongside reduced net losses and a strong cash position for the next 12 months.

Summary

• Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies.
• The company has strategically deprioritized its oncology programs (NKX019 for B-cell malignancies and NKX101 for hematologic malignancies) to concentrate resources on NKX019 for autoimmune diseases.
• NKX019 is currently in Phase 1 clinical trials (Ntrust-1 for Lupus Nephritis and Primary Membranous Nephropathy; Ntrust-2 for Systemic Sclerosis, Idiopathic Inflammatory Myopathy, and ANCA-associated vasculitis).
• Investigator-sponsored trials (ISTs) for NKX019 are also underway for Systemic Lupus Erythematosus (SLE) and Myasthenia Gravis (MG).
• In November 2025, deep B-cell depletion was observed in patients treated with NKX019 using fludarabine (Flu) and cyclophosphamide (Cy) lymphodepleting conditioning (LD), compared to partial depletion with Cy alone.
• The company reported a net loss of $104.1 million for the year ended December 31, 2025, an improvement from $108.8 million in 2024.
• Research and development expenses decreased to $90.4 million in 2025 from $96.7 million in 2024, primarily due to lower personnel costs and deprioritized programs, partially offset by increased clinical spending on NKX019 for autoimmune diseases.
• General and administrative expenses slightly increased to $31.6 million in 2025 from $31.5 million in 2024, including a $4.9 million increase in severance expenses due to a March 2025 workforce reduction.
• As of December 31, 2025, Nkarta had $295.1 million in cash, cash equivalents, restricted cash, and investments, which is estimated to be sufficient for at least 12 months.
• The company executed a reduction in workforce in March 2025, impacting 53 positions (approximately 34% of its workforce), to decrease costs and streamline operations.
• Nkarta's authorized capital stock consists of 200,000,000 shares of common stock and 54,350,179 shares of preferred stock, with 71,078,531 common shares outstanding as of December 31, 2025.
• The company holds a significant patent portfolio with 55 issued utility patents and 200 pending applications, with estimated expiration dates ranging from 2024 to 2046.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. The strategic focus on autoimmune diseases and initial clinical observations of B-cell depletion are encouraging, and the reduced net loss and solid cash runway provide stability. However, the early stage of clinical trials, significant ongoing losses, and persistent enrollment challenges temper the overall sentiment.

Positives

• Net loss decreased to $104.1 million in 2025 from $108.8 million in 2024, indicating improved financial performance.
• Cash, cash equivalents, restricted cash, and investments totaled $295.1 million as of December 31, 2025, providing a liquidity runway for at least 12 months.
• Deep B-cell depletion was observed in all patients treated with NKX019 using Flu and Cy lymphodepleting conditioning, suggesting enhanced therapeutic potential.
• The company has a clear strategic focus on B-cell mediated autoimmune diseases, which could streamline development efforts and resource allocation.
• Nkarta possesses proprietary technologies for NK cell expansion, persistence, targeting, genome editing, and cryopreservation, offering a competitive advantage.
• The company has established internal cGMP manufacturing capabilities, reducing reliance on third parties for early-stage clinical supply and potentially lowering future costs.

Negatives

• Nkarta has incurred significant operating losses since its inception in 2015, with an accumulated deficit of $648.3 million as of December 31, 2025.
• The company has never generated revenue from product sales and does not anticipate profitability in the foreseeable future.
• Oncology programs (NKX019 for B-cell malignancies and NKX101) have been deprioritized, representing a setback in previous development areas.
• Enrollment and retention of patients in clinical trials, particularly Ntrust-1 and Ntrust-2, have faced significant challenges and may continue to do so.
• The company relies on a sole supplier (Miltenyi) for certain critical manufacturing materials, posing a supply chain risk.
• A reduction in workforce in March 2025, affecting 34% of employees, may negatively impact company culture and employee morale.
• The market price for common stock is highly volatile, and future capital raises may cause dilution to existing stockholders.

Risks

• Limited operating history and no products approved for sale, leading to uncertainty about future success or viability.
• Expectation of continued significant losses for the foreseeable future, requiring substantial additional capital.
• Dependence on the success of the CAR NK-cell technology platform, which is a novel therapeutic approach with significant development and commercialization challenges.
• Clinical development is lengthy, expensive, and has an uncertain outcome, with potential for substantial delays due to factors outside the company's control.
• Clinical data supporting CD19-targeted cell therapies for autoimmune diseases are limited, and NKX019 may not provide the same therapeutic benefit or be competitive.
• Enrollment and retention of patients in clinical trials are expensive, time-consuming, and subject to multiple external factors, potentially causing delays.
• Certain aspects of CAR NK cell function and production are unknown or poorly understood, potentially requiring re-engineering, delays, and additional expenses.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results, and interim data may differ materially from final data.
• Serious adverse events from NKX019 or competing product candidates could halt or delay clinical development, especially given lower tolerance for adverse events in autoimmune populations.
• Intense competition from academic institutions and other biopharmaceutical companies developing similar or alternative cellular immunotherapy product candidates.
• Manufacturing process is novel and complex, with potential difficulties in production, internal manufacturing, and providing sufficient supply for trials or commercialization.
• Reliance on third parties for certain manufacturing materials increases the risk of insufficient quantities or unacceptable costs.
• Delays in commissioning and receiving regulatory approvals for manufacturing facilities could delay development plans and limit revenue generation.
• Optimal donor and manufacturing parameters for product candidates have not been definitively established, hindering optimization and addressing safety/efficacy issues.
• Termination of the license agreement with National University of Singapore and St. Jude Children's Research Hospital, Inc. could result in loss of rights to key NK-cell engineering platform components.
• Patent protection may not be sufficiently robust, allowing competitors to develop similar or identical products.
• Claims of infringing, misappropriating, or violating third-party intellectual property rights could be costly and delay commercialization.
• Failure to develop or secure marketing, sales, and distribution capabilities would prevent successful commercialization of approved products.
• Approved product candidates could be subject to regulatory limitations, including restrictions on use, labeling, advertising, and post-approval studies.
• Market opportunities for product candidates may be limited, and if smaller than expected, revenues could be materially adversely affected.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products could limit market access and revenue generation.
• Healthcare reform initiatives and other administrative and legislative proposals could harm the business by increasing cost containment pressures.
• Failure to comply with evolving global privacy laws, including HIPAA, CCPA, CPRA, and GDPR, could lead to penalties, lawsuits, and reputational harm.
• Computer system interruptions or security breaches could disrupt product development, operations, and lead to liability.
• Misuse of artificial intelligence could pose security risks to confidential information and intellectual property.
• Macroeconomic conditions, including rising inflation, interest rates, and supply chain constraints, could adversely affect business and financial condition.
• Acquisitions or strategic collaborations may increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.

Future Outlook

Nkarta expects to continue incurring significant operating losses as it advances NKX019 and future product candidates through clinical development and seeks regulatory approvals. The company anticipates substantial increases in R&D expenses, particularly for pivotal trials, and will require additional capital, likely through equity or debt financings or strategic partnerships. The company believes its current cash and investments are sufficient for at least the next 12 months, but this forecast is subject to risks and uncertainties. Nkarta plans to continue assessing opportunities for further expansion of NKX019 into additional indications and to advance its CAR NK platform for new product candidates.

Management Comments

• Management believes that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible, and unencumbered by safety concerns.
• Management believes that engineered NK cells have the potential to be effective and accessible therapies for autoimmune diseases and other diseases, be well tolerated, and avoid some of the toxicities observed with other cell therapies.
• Management believes that internal cGMP manufacturing capabilities will facilitate clinical product supply, lower the risk of manufacturing disruptions, and enable more cost-effective manufacturing for both clinical and, if successfully developed, commercial supply.
• Management believes that the modular nature of our platform and the proprietary technologies we use for the multiplex engineering of NK cells are advantages that can support the generation of new Investigational New Drugs (INDs) for product candidates with enhanced properties.
• Management believes that our current facilities will be sufficient to meet our anticipated requirements for non-pivotal and pivotal clinical trials, as well as our potential commercial launch.
• Management believes that our values are the foundations for our team and our behaviors for promoting creativity, innovation and productivity.

Industry Context

StockSavvy.ai notes that Nkarta's strategic pivot to autoimmune diseases positions it in a highly competitive and evolving field. While CD19-targeted CAR T-cell therapies have shown promise in academic studies for autoimmune conditions, Nkarta's allogeneic CAR NK approach aims to address the accessibility and toxicity limitations of autologous CAR T-cells. The company faces significant competition from both established biopharmaceutical companies and other cell therapy developers, including those pursuing autologous and allogeneic cell therapies, T-cell/NK-cell engagers, and monoclonal antibodies. The lack of FDA-approved cell therapies for autoimmune diseases highlights the novelty and inherent risks, but also the significant unmet medical need and market opportunity Nkarta is targeting.

Comparison to Industry Standards

• Nkarta's allogeneic CAR NK-cell therapy (NKX019) aims to offer advantages in tolerability, availability, and manufacturing consistency/cost compared to approved autologous CAR T-cell therapies (e.g., those from Novartis, Gilead, Bristol-Myers Squibb) which are associated with higher rates of cytokine release syndrome (CRS) and neurotoxicity.
• The observed deep B-cell depletion with Flu and Cy lymphodepleting conditioning for NKX019 aligns with the mechanism of action seen in academic studies of CD19 CAR T-cell therapies for autoimmune diseases, such as the Mackensen et al. (2022) and Müller et al. (2024) studies in SLE patients, which reported significant clinical improvement and remission.
• Nkarta's manufacturing process, while novel and complex, seeks to achieve scaled production for broader patient access, contrasting with the individualized and labor-intensive manufacturing of autologous therapies.
• The company competes directly with other firms developing CD19-targeted therapies for autoimmune diseases, including AstraZeneca, Autolus, Bristol-Myers Squibb, Cabaletta, Cartesian, Gilead, iCell, Juventas, JW Therapeutics, Kyverna, Miltenyi, Novartis, Roche, Rui Therapeutics, and Synthekine (autologous cell therapies), and Adicet, Allogene, Artiva, Atara, CRISPR Therapeutics, Fate Therapeutics, TG Therapeutics, and Sana Biotechnology (allogeneic cell therapies).

Management Changes

Corporate Governance

Legal Proceedings

• There are currently no claims or actions pending against Nkarta, Inc. that are likely to have a material adverse effect on its business, results of operations, financial condition, or growth prospects.

Related Party Transactions

• No specific related party dealings beyond standard executive compensation and director independence disclosures are detailed in the provided filing.

Stakeholder Impact

• Shareholders: Face potential dilution from future capital raises, volatility in stock price, and limited influence on corporate decisions due to concentrated ownership and anti-takeover provisions.
• Employees: Experienced a significant reduction in workforce (34% in March 2025), which may negatively impact morale and retention, but remaining employees benefit from competitive compensation and well-being programs.
• Patients: Stand to benefit from the potential development of novel, accessible, and well-tolerated NK cell therapies for autoimmune diseases, but face risks associated with early-stage clinical trials and potential adverse events.
• Third-party Payors: Will play a critical role in coverage and reimbursement decisions for any approved products, with significant uncertainty regarding pricing and market acceptance.
• Suppliers/Contractors: The company's reliance on a sole supplier for critical manufacturing components creates risk for supply chain disruptions, while other third-party manufacturers and CROs are essential for clinical development.

Next Steps

• Continue the clinical development of NKX019 in Ntrust-1 (LN/pMN) and Ntrust-2 (scleroderma, myositis, AAV) clinical trials.
• Monitor ongoing investigator-sponsored trials (ISTs) for NKX019 in SLE and MG.
• Advance additional product candidates to clinical trials based on the CAR NK platform.
• Continue scale-up and optimization of manufacturing processes and prepare for commercial manufacturing.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Establish or secure marketing, sales, and distribution capabilities for any approved products.
• Evaluate enabling, adjacent, or potentially competing technologies and seek licenses or collaborations to advance the platform.
• Potentially pursue additional capital raises through equity, debt, or partnerships to fund operations and pivotal trials.

Key Dates

Recommendation

A 'hold' recommendation is appropriate for Nkarta, Inc. given its current stage. While the strategic focus on autoimmune diseases with NKX019 shows promise and the company has a solid cash runway for the near term, the clinical trials are still in early phases. Significant R&D expenses and continued net losses are expected for a clinical-stage biopharmaceutical company. Investors should await more mature clinical data from the ongoing Phase 1 trials and further clarity on the path to pivotal studies and potential commercialization before making more aggressive investment decisions. The recent workforce reduction and deprioritization of oncology programs, while aimed at efficiency, also highlight the inherent risks and challenges in drug development.

Keywords

NK cell therapy, autoimmune disease, NKX019, CAR NK, Lupus Nephritis, Primary Membranous Nephropathy, Systemic Sclerosis, Idiopathic Inflammatory Myopathy, ANCA-associated vasculitis, Myasthenia Gravis, Systemic Lupus Erythematosus, clinical-stage biopharmaceutical, allogeneic, off-the-shelf, CD19-targeted, SEC filing, 10-K, biotechnology, cell engineering, cGMP manufacturing, intellectual property, clinical trials, financial results